Cansino Biologics Inc (688185) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.006x

Based on the latest financial reports, Cansino Biologics Inc (688185) has a cash flow conversion efficiency ratio of 0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥30.53 Million ≈ $4.47 Million USD) by net assets (CN¥4.93 Billion ≈ $721.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cansino Biologics Inc (688185) net asset quality to measure how much of total assets are equity-financed.

Cansino Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Cansino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 688185 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Cansino Biologics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cansino Biologics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Clinica Baviera MC:CBAV	0.146x
IRB-Brasil Resseguros S.A. SA:IRBR3	0.015x
Montepino Logistica SOCIMI S.A. PA:MLMTP	N/A
Mesnac Co Ltd SHE:002073	0.028x
Sparekassen Sjaelland-Fyn A/S CO:SPKSJF	0.107x
Tian Jin Motor Dies Co Ltd SHE:002510	0.053x
Corsair Gaming Inc NASDAQ:CRSR	0.045x
Kodiak AI, Inc. Common Stock NASDAQ:KDK	1.297x

Annual Cash Flow Conversion Efficiency for Cansino Biologics Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of Cansino Biologics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688185 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥12.11 Billion ≈ $1.77 Billion	CN¥77.86 Million ≈ $11.39 Million	0.006x	+118.72%
2024-12-31	CN¥4.92 Billion ≈ $719.24 Million	CN¥-168.79 Million ≈ $-24.70 Million	-0.034x	+80.18%
2023-12-31	CN¥5.29 Billion ≈ $773.72 Million	CN¥-916.25 Million ≈ $-134.08 Million	-0.173x	+33.48%
2022-12-31	CN¥7.25 Billion ≈ $1.06 Billion	CN¥-1.89 Billion ≈ $-276.22 Million	-0.261x	-210.54%
2021-12-31	CN¥8.55 Billion ≈ $1.25 Billion	CN¥2.01 Billion ≈ $294.79 Million	0.236x	+404.82%
2020-12-31	CN¥6.07 Billion ≈ $888.36 Million	CN¥-469.39 Million ≈ $-68.69 Million	-0.077x	+33.19%
2019-12-31	CN¥1.47 Billion ≈ $215.18 Million	CN¥-170.19 Million ≈ $-24.90 Million	-0.116x	+52.98%
2018-12-31	CN¥502.32 Million ≈ $73.50 Million	CN¥-123.64 Million ≈ $-18.09 Million	-0.246x	-165.51%
2017-12-31	CN¥607.33 Million ≈ $88.87 Million	CN¥-56.30 Million ≈ $-8.24 Million	-0.093x	+42.17%
2016-12-31	CN¥214.47 Million ≈ $31.38 Million	CN¥-34.38 Million ≈ $-5.03 Million	-0.160x	--

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic

Market Cap

$842.34 Million

CN¥5.76 Billion CNY

Market Cap Rank

#9652 Global

#2461 in China

Share Price

CN¥50.33

Change (1 day)

-1.78%

52-Week Range

CN¥47.90 - CN¥88.19

All Time High

CN¥773.75